Literature DB >> 6436464

Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection.

T B Cooper, R F Suckow, A Glassman.   

Abstract

A method for the determination of bupropion and its three major basic metabolites in plasma is described. Following an extraction from alkaline plasma into 1.5% v/v isoamyl alcohol in n-heptane, a portion of the acid-backwashed extract was injected onto a column packed with trimethylsilyl reverse-phase material and eluted with a phosphate buffer-acetonitrile (80:20) mobile phase containing an ion-pairing reagent and triethylamine. The compounds were detected with a dual-wavelength UV detector (214 and 254 nm) to optimize sensitivity and facilitate simultaneous detection. The method provides an absolute recovery of approximately 85% for bupropion and approximately 98% for the metabolites. Day-to-day reproducibility did not exceed 4.0% for all compounds. The detection limits were approximately 5 ng/mL for bupropion and 100 ng/mL for the major metabolites. The limit of 100 ng/mL for metabolite quantitation is imposed by the internal standard concentration selected for steady-state studies. In single-dose pharmacokinetic studies, 10% of the steady-state concentration of internal standard was used; this permitted a 10-ng/mL lower limit of detection. Steady-state plasma levels of bupropion and the metabolites from eight different patients are presented.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436464     DOI: 10.1002/jps.2600730820

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  The effect of experimentally-induced renal failure on accumulation of bupropion and its major basic metabolites in plasma and brain of guinea pigs.

Authors:  C L DeVane; S C Laizure; D F Cameron
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Metabolism of bupropion by carbonyl reductases in liver and intestine.

Authors:  Jamie N Connarn; Xinyuan Zhang; Andrew Babiskin; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2015-04-22       Impact factor: 3.922

Review 5.  Formation of active metabolites of psychotropic drugs. An updated review of their significance.

Authors:  S Caccia; S Garattini
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

6.  Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice.

Authors:  M Imad Damaj; Sheri D Grabus; Hernan A Navarro; Robert E Vann; Jonathan A Warner; Lindsey S King; Jenny L Wiley; Bruce E Blough; Ronald J Lukas; F Ivy Carroll
Journal:  J Pharmacol Exp Ther       Date:  2010-06-24       Impact factor: 4.030

7.  Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.

Authors:  Jun-Sheng Wang; C Lindsay DeVane; B Bryan Gibson; Jennifer L Donovan; John S Markowitz; Hao-Jie Zhu
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

Review 8.  New mechanisms and perspectives in nicotine withdrawal.

Authors:  K J Jackson; P P Muldoon; M De Biasi; M I Damaj
Journal:  Neuropharmacology       Date:  2014-11-26       Impact factor: 5.250

9.  Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Xiaoming Wang; Daria I Vernikovskaya; Doaa R Abdelrahman; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  J Pharm Biomed Anal       Date:  2012-05-23       Impact factor: 3.935

10.  Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Raghotham Reddy Pinninti; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2009-02       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.